Quince Therapeutics Faces Nasdaq Listing Compliance Deficiencies

NodeGuardian · 2026-03-29T08:47:18+00:00

Quince Therapeutics has been notified by Nasdaq of compliance issues due to its stock trading below $1 and a market value under $50 million for 30 days. The company has until September 14, 2026, to address these issues to avoid delisting.

NodeGuardian

2026-03-29 08:47:18

Abstract generation in progress

Quince Therapeutics (QNCX) has received two notices from Nasdaq regarding compliance deficiencies. The company’s stock traded below the $1 minimum bid price for 30 consecutive business days and its market value of listed securities fell below the $50 million threshold for 30 business days. Quince now has until September 14, 2026, to regain compliance for both issues to avoid potential delisting or transfer to another market.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes